Traders assign an 85.5% implied probability to no new COVID variant of concern before 2027 because SARS-CoV-2 continues evolving primarily within established Omicron sublineages such as XFG, NB.1.8.1, and BA.3.2 without triggering WHO or ECDC escalation criteria. BA.3.2, first detected in South Africa in late 2024 and spreading to over 20 countries by early 2026, carries dozens of spike mutations yet shows no evidence of increased severity, hospitalization rates, or substantial vaccine escape that would warrant VOC status. Public health agencies report low overall risk assessments, ongoing genomic surveillance, and high population immunity from prior infections and updated vaccines, all of which dampen the potential impact of new mutations. With no VOC designations since earlier Omicron waves and no recent catalysts indicating a shift, market pricing reflects sustained stability through the end of 2026.